Literature DB >> 28328682

Early tranexamic acid administration ameliorates the endotheliopathy of trauma and shock in an in vitro model.

Lawrence N Diebel1, Jonathan V Martin, David M Liberati.   

Abstract

BACKGROUND: Systemic vascular endothelial injury is a consequence of trauma (T)/hemorrhagic shock (HS) which results in disturbances of coagulation, inflammation, and endothelial barrier integrity. The effect of T/HS on the endothelium (endotheliopathy of trauma [EoT]) is of intense research interest and may lead to EoT-directed therapies. Administration of tranexamic acid (TXA) in trauma patients is associated with a survival benefit and fewer complications if given early after injury. Mechanisms for this protective effect include the antifibrinolytic and anti-inflammatory effects of TXA. We hypothesized that "early" administration of TXA would abrogate vascular endothelial cell activation and injury after T/HS. This was studied in vitro.
METHODS: Confluent human umbilical vein endothelial cells were exposed to hydrogen peroxide and/or epinephrine to stimulate post-T/HS oxidant exposure and/or sympathoadrenal activation. TXA was added 15 minutes, 60 minutes, or 120 minutes after H2O2 and/or epinephrine challenge. Endothelial cell injury was indexed by cell monolayer permeability, intracellular adhesion molecule expression, soluble thrombomodulin, syndecan release (marker for glycocalyx injury), tissue type plasminogen activator (tPA), plasminogen activator inhibitor-1 (PAI-1) and angiopoietin-2/angiopoietin-1 ratio (APO-2/APO-1).
RESULTS: Endothelial activation and injury as indexed by permeability, ICAM expression, soluble thrombomodulin were increased by H2O2 and/or epinephrine exposure. Biomarkers of endothelial coagulation profile (tPA/PAI-1) demonstrated a profibrinolytic profile (increased tPA and tPA/PAI-1 ratio) after challenge by H2O2 and/or epinephrine. Vascular "leakiness" as indexed by APO-2/APO-1 ratio was also evident. The most profound effects were noted with H2O2/epinephrine exposure. TXA administration within 60 minutes of H2O2/epinephrine challenge abolished the adverse effects noted on the endothelial-glycocalyx "double barrier." TXA administration after 60 minutes was not protective.
CONCLUSION: Antifibrinolytic and other protective effects of TXA administration on endothelial injury are time-dependent. This study supports the concept that the clinical efficacy of TXA administration requires "early administration."

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28328682     DOI: 10.1097/TA.0000000000001445

Source DB:  PubMed          Journal:  J Trauma Acute Care Surg        ISSN: 2163-0755            Impact factor:   3.313


  12 in total

1.  Does Tranexamic Acid Improve Clot Strength in Severely Injured Patients Who Have Elevated Fibrin Degradation Products and Low Fibrinolytic Activity, Measured by Thrombelastography?

Authors:  Hunter B Moore; Ernest E Moore; Michael P Chapman; Kirk C Hansen; Mitchell J Cohen; Frederic M Pieracci; James Chandler; Angela Sauaia
Journal:  J Am Coll Surg       Date:  2019-03-29       Impact factor: 6.113

2.  Tranexamic acid suppresses the release of mitochondrial DNA, protects the endothelial monolayer and enhances oxidative phosphorylation.

Authors:  Igor Prudovsky; Damien Carter; Doreen Kacer; Monica Palmeri; Tee Soul; Chloe Kumpel; Kathleen Pyburn; Karyn Barrett; Victoria DeMambro; Ilya Alexandrov; Irina Brandina; Robert Kramer; Joseph Rappold
Journal:  J Cell Physiol       Date:  2019-04-02       Impact factor: 6.384

Review 3.  Does Tranexamic Acid Reduce the Blood Loss in Various Surgeries? An Umbrella Review of State-of-the-Art Meta-Analysis.

Authors:  Pan Hong; Ruikang Liu; Saroj Rai; JiaJia Liu; Yuhong Ding; Jin Li
Journal:  Front Pharmacol       Date:  2022-05-19       Impact factor: 5.988

4.  Shock-Induced Endothelial Dysfunction is Present in Patients With Occult Hypoperfusion After Trauma.

Authors:  Heather R Kregel; Gabrielle E Hatton; Kayla D Isbell; Hanne H Henriksen; Jakob Stensballe; Per I Johansson; Lillian S Kao; Charles E Wade
Journal:  Shock       Date:  2022-01-01       Impact factor: 3.533

5.  Elevated Syndecan-1 after Trauma and Risk of Sepsis: A Secondary Analysis of Patients from the Pragmatic, Randomized Optimal Platelet and Plasma Ratios (PROPPR) Trial.

Authors:  Shuyan Wei; Erika Gonzalez Rodriguez; Ronald Chang; John B Holcomb; Lillian S Kao; Charles E Wade
Journal:  J Am Coll Surg       Date:  2018-09-21       Impact factor: 6.113

6.  Graft glycocalyx degradation in human liver transplantation.

Authors:  Arie Passov; Alexey Schramko; Heikki Mäkisalo; Arno Nordin; Sture Andersson; Eero Pesonen; Minna Ilmakunnas
Journal:  PLoS One       Date:  2019-08-15       Impact factor: 3.240

7.  Tranexamic acid is associated with reduced mortality, hemorrhagic expansion, and vascular occlusive events in traumatic brain injury - meta-analysis of randomized controlled trials.

Authors:  Julius July; Raymond Pranata
Journal:  BMC Neurol       Date:  2020-04-06       Impact factor: 2.474

Review 8.  Studying the Endothelial Glycocalyx in vitro: What Is Missing?

Authors:  Andrew B Haymet; Nicole Bartnikowski; Emily S Wood; Michael P Vallely; Angela McBride; Sophie Yacoub; Scott B Biering; Eva Harris; Jacky Y Suen; John F Fraser
Journal:  Front Cardiovasc Med       Date:  2021-04-14

9.  Tranexamic acid administration in the field does not affect admission thromboelastography after traumatic brain injury.

Authors:  Alexandra L Dixon; Belinda H McCully; Elizabeth A Rick; Elizabeth Dewey; David H Farrell; Laurie J Morrison; Jason McMullan; Bryce R H Robinson; Jeannie Callum; Brian Tibbs; David J Dries; Jonathan Jui; Rajesh R Gandhi; John S Garrett; Myron L Weisfeldt; Charles E Wade; Tom P Aufderheide; Ralph J Frascone; John M Tallon; Delores Kannas; Carolyn Williams; Susan E Rowell; Martin A Schreiber
Journal:  J Trauma Acute Care Surg       Date:  2020-11       Impact factor: 3.697

10.  The Immunologic Effect of Early Intravenous Two and Four Gram Bolus Dosing of Tranexamic Acid Compared to Placebo in Patients With Severe Traumatic Bleeding (TAMPITI): A Randomized, Double-Blind, Placebo-Controlled, Single-Center Trial.

Authors:  Philip C Spinella; Kimberly A Thomas; Isaiah R Turnbull; Anja Fuchs; Kelly Bochicchio; Douglas Schuerer; Stacey Reese; Adrian A Coleoglou Centeno; Christopher B Horn; Jack Baty; Susan M Shea; M Adam Meledeo; Anthony E Pusateri; Jerrold H Levy; Andrew P Cap; Grant V Bochicchio
Journal:  Front Immunol       Date:  2020-09-08       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.